FLC Capital Advisors Buys New Holdings in Sanofi $SNY

FLC Capital Advisors bought a new stake in Sanofi (NASDAQ:SNY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,751 shares of the company’s stock, valued at approximately $278,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. Brighton Jones LLC raised its holdings in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares in the last quarter. GAMMA Investing LLC raised its holdings in Sanofi by 58.7% during the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after purchasing an additional 2,241 shares in the last quarter. Sowell Financial Services LLC acquired a new stake in Sanofi during the first quarter worth approximately $328,000. Altrius Capital Management Inc raised its holdings in Sanofi by 1.0% during the first quarter. Altrius Capital Management Inc now owns 163,593 shares of the company’s stock worth $9,073,000 after purchasing an additional 1,653 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in Sanofi by 1.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 33,328 shares of the company’s stock worth $1,848,000 after purchasing an additional 318 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $50.62 on Monday. The firm has a market capitalization of $124.30 billion, a P/E ratio of 12.17, a PEG ratio of 1.23 and a beta of 0.51. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company’s fifty day moving average is $48.49 and its two-hundred day moving average is $49.56. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.Sanofi’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.73 earnings per share. Analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.